Diletta Fontana

15PUBLICATIONS
59CO-AUTHORS
Molecular targetsSolid tumoursGene and molecular therapyHaematologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jan 21, 2025
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.

Richard Junior Zapata Dongo, Diletta Fontana, Luca Mologni

|Oct 31, 2024
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.

Matteo Villa, Geeta G Sharma, Federica Malighetti

|May 15, 2024
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.

Diletta Fontana, Federica Malighetti, Matteo Villa

|Mar 06, 2024
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients.

Matteo Villa, Federica Malighetti, Elisa Sala

|Feb 06, 2024
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.

Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella

|Jan 09, 2024
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.

Ilaria Crespiatico, Mattia Zaghi, Cristina Mastini

Pageof 3

Frequent Collaborators

7 joint publications

Rocco Piazza

6 joint publications

Luca Mologni

6 joint publications

Carlo Gambacorti-Passerini

5 joint publications

Matteo Villa